Biomarker-directed therapy in black and white men with metastatic castration-resistant prostate cancer (mCRPC).

被引：0
|
作者：
Hwang, Clara
Henderson, Nicholas
Cackowski, Frank Cameron
Pilling, Amanda
Jang, Albert
Rothstein, Shoshana
Labriola, Matthew
Park, Joseph J.
Ghose, Alyssa
Bilen, Mehmet Asim
Kilari, Deepak
Tripathi, Abhishek
Garje, Rohan
Koshkin, Vadim S.
Schweizer, Michael Thomas
Armstrong, Andrew J.
Mckay, Rana R.
Dorff, Tanya B.
Alva, Ajjai Shivaram
Barata, Pedro C.
机构：
[1] Henry Ford Hlth Syst, Detroit, MI USA
[2] Univ Michigan, Dept Biostat, Ann Arbor, MI USA
[3] Barbara Ann Karmanos Canc Inst, Detroit, MI USA
[4] Tulane Univ, Sch Med, New Orleans, LA USA
[5] Duke Univ, Div Med Oncol, Durham, NC USA
[6] Univ Michigan, Dept Med, Div Hematol & Oncol, Ann Arbor, MI USA
[7] Univ Michigan, Ann Arbor, MI USA
[8] Emory Univ, Sch Med, Dept Hematol & Med Oncol, Atlanta, GA USA
[9] Med Coll Wisconsin, Froedtert Canc Ctr, Dept Med, Milwaukee, WI USA
[10] Univ Oklahoma, Hlth Sci Ctr, Stephenson Canc Ctr, Oklahoma City, OK USA
[11] Univ Iowa, Div Hematol Oncol, Dept Internal Med, Iowa City, IA USA
[12] Univ Calif San Francisco, San Francisco, CA USA
[13] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA USA
[14] Duke Univ, Sch Med, Duke Canc Inst, Ctr Prostate & Urol Canc, Durham, NC USA
[15] Univ Calif San Diego Hlth, La Jolla, CA USA
[16] City Hope Comprehens Canc Ctr, Duarte, CA USA
[17] Univ Michigan, Rogel Comprehens Canc Ctr, Ann Arbor, MI USA
[18] Tulane Univ, Sch Med, New Orleans, LA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5013
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer
    Hwang, Clara
    Henderson, Nicholas C.
    Chu, Shih-Chun
    Holland, Brandon
    Cackowski, Frank C.
    Pilling, Amanda
    Jang, Albert
    Rothstein, Shoshana
    Labriola, Matthew
    Park, Joseph J.
    Ghose, Alyssa
    Bilen, Mehmet A.
    Mustafa, Seema
    Kilari, Deepak
    Pierro, Michael J.
    Thapa, Bicky
    Tripathi, Abhishek
    Garje, Rohan
    Ravindra, Aditya
    Koshkin, Vadim S.
    Hernandez, Erik
    Schweizer, Michael T.
    Armstrong, Andrew J.
    Mckay, Rana R.
    Dorff, Tanya B.
    Alva, Ajjai S.
    Barata, Pedro C.
    JAMA NETWORK OPEN, 2023, 6 (09) : e2334208
  • [2] Has the Time Arrived for Biomarker-Directed Therapy in Castration-Resistant Prostate Cancer?
    Taplin, Mary-Ellen
    Balk, Steven P.
    JAMA ONCOLOGY, 2015, 1 (05) : 577 - 579
  • [3] Avelumab in metastatic castration-resistant prostate cancer (mCRPC).
    Fakhrejahani, Farhad
    Madan, Ravi Amrit
    Dahut, William L.
    Bilusic, Marijo
    Karzai, Fatima
    Cordes, Lisa M.
    Strauss, Julius
    Schlom, Jeffrey
    Gulley, James L.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [4] ARN-509 in men with metastatic castration-resistant prostate cancer (mCRPC)
    Rathkopf, Dana E.
    Antonarakis, Emmanuel S.
    Shore, Neal D.
    Tutrone, Ronald
    Alumkal, Joshi J.
    Ryan, Charles J.
    Saleh, Mansoor N.
    Hauke, Ralph J.
    Maneval, Edna Chow
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [5] Pembrolizumab in men with heavily treated metastatic castration-resistant prostate cancer (mCRPC).
    Tucker, Matthew D.
    Zhu, Jason
    Berry, William R.
    Ramalingam, Sundhar
    Zhang, Tian
    Harrison, Michael Roger
    Wu, Yuan
    Healy, Patrick
    George, Daniel J.
    Armstrong, Andrew J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [6] Avelumab in metastatic castration-resistant prostate cancer (mCRPC).
    Fakhrejahani, Farhad
    Madan, Ravi Amrit
    Dahut, William L.
    Karzai, Fatima
    Cordes, Lisa M.
    Schlom, Jeffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [7] Bipolar androgen therapy (BAT) plus olaparib in men with metastatic castration-resistant prostate cancer (mCRPC)
    Schweizer, M.
    Gulati, R.
    Yezefski, T.
    Cheng, H.
    Sievers, C.
    Dumpit, R.
    Alexander, K.
    McDonald, N.
    Lai, M.
    Nega, K.
    Hammond, J.
    Grivas, P.
    Hsieh, A.
    Montgomery, B.
    Nelson, P.
    Yu, E.
    ANNALS OF ONCOLOGY, 2021, 32 : S639 - S640
  • [8] Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC).
    Maughan, Benjamin Louis
    Suzman, Daniel L.
    Nadal, Rosa
    Bassi, Sunakshi
    Schweizer, Michael Thomas
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [9] Body composition and clinical outcomes in men with metastatic castration-resistant prostate cancer (mCRPC)
    Hahn, A. W.
    Tidwell, R. S.
    Surasi, D. S.
    Msaouel, P.
    Efstathiou, E.
    Zurita-Saavedra, A. J.
    Tu, S-M.
    McQuade, J. L.
    Fogelman, D.
    Starbuck, M. W.
    Subudhi, S. K.
    Corn, P.
    Pilie, P. G.
    Aparicio, A.
    Logothetis, C.
    ANNALS OF ONCOLOGY, 2020, 31 : S538 - S538
  • [10] PSA decline and objective response rates in White (W), Black (B), and Asian men with metastatic castration-resistant prostate cancer (mCRPC).
    Halabi, Susan
    Dutta, Sandipan
    Chi, Kim N.
    Tangen, Catherine M.
    Xuan, Mengdi
    Petrylak, Daniel Peter
    Araujo, John C.
    Fizazi, Karim
    Quinn, David I.
    Morris, Michael J.
    Higano, Celestia S.
    Tannock, Ian
    Small, Eric Jay
    Kelly, William Kevin
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345